 |
 |
| Back Issues |
|
|
|
|
ACS Members can sign up to receive C&EN e-mail newsletter.  |
|
|
 Join ACS |
|
|||||||||
|
PHARMACEUTICAL BUSINESS
Schering-Plough says it expects that an ongoing government probe of its sales, marketing, and clinical trial practices will result in an indictment. Schering-Plough says it has received a letter from the U.S. Attorney's Office for the District of Massachusetts advising the company that its subsidiary, Schering Corp., is the target of a federal grand jury investigation. The company says it "understands that, based on Department of Justice guidelines, receipt of a 'target' letter indicates the government intends to pursue an indictment and believes it has substantial evidence to support that indictment." The probe, announced in November 2002, centers on four areas: providing remuneration, such as drug samples, clinical trial grants, and other items or services, to managed health care organizations, physicians, and others to induce the purchase of Schering products for which payment was made through federal programs; sale of misbranded or unapproved drugs; submitting false pharmaceutical pricing information to the government; and document destruction and obstruction of justice relating to the government's investigation. Schering says it has implemented changes to its sales, marketing, and clinical trial practices and is continuing to review those practices to ensure compliance with relevant laws and regulations. |
|||||||||
|
Chemical & Engineering News |
|||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
